Compare StocksMRNA vs V

Moderna, Inc. (MRNA) vs Visa Inc. (V): Which Is the Better Buy in 2026?

As of 2026-06-19, MRNA is overvalued at $64, with a DCF intrinsic value of $6 and a margin of safety of -963%. V is fairly valued at $327, with an intrinsic value of $304 and a margin of safety of -8%. Of the two, V has the wider margin of safety.

MRNA
Moderna, Inc.
$63.96
VS
V
Visa Inc.
$327.24

Rewards

MRNA
    V
    • Visa Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
    • Gross margin of 97.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
    • Visa Inc. scores 99/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.

    Risks

    MRNA
    • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
    • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
    • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
    V
    • Insiders have sold $14.2M worth of stock in the past 3 months — significant insider liquidation.

    Key Valuation Metrics

    Learn more →
    MRNA
    V
    Valuation
    $-20.00M
    Free Cash Flow
    $20.84B
    -0.08%
    FCF Yield
    3.35%
    N/A
    Trailing P/E
    28.55
    -15.21
    Forward P/E
    22.02
    Quality & Moat
    -26.47%
    ROIC
    38.39%
    -36.56%
    ROE
    60.35%
    -69.89%
    Gross Margin
    97.78%
    N/A
    PEG Ratio
    1.46
    Balance Sheet Safety
    Net cash
    Net Debt / Equity
    0.28
    N/A
    Interest Coverage
    N/A
    N/A
    Net Debt / EBITDA
    0.33
    0.00%
    Dividend Yield
    0.80%
    MRNA: 2Ties: 1V: 6
    MRNAV

    Historical Fundamentals

    Learn more →
    MRNA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    V

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    MRNA
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-11.10B
    Δ Market Cap
    $-57.53B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    V
    $5.50
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $44.47B
    Δ Market Cap
    +$244.54B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    MRNA
    962.8% Overvalued
    Price is 962.8% above estimated fair value
    Current Price: $63.96
    Fair Value: $6.02
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    V
    7.6% Overvalued
    Price is 7.6% above estimated fair value
    Current Price: $327.24
    Fair Value: $304.21
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    MRNA

    Requires positive FCF to compute implied growth rate.

    V

    What growth rate is the market pricing in at $327?

    +13.9%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +13.4%

    The market implies +13.9% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +13.4%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    MRNA
    17/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    V
    99/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

    Forensic Accounting

    Learn more →
    MRNA

    Insufficient data for Beneish M-Score calculation (requires 2+ years).

    V
    -2.50
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    MRNA
    Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
    No. of Institutional Holders1,044
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    V
    Insiders 0.1%Institutions 91.7%Retail & Other 8.2%
    No. of Institutional Holders5,856
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    MRNA
    0
    Buys (3M)
    0
    Buys (12M)
    SAGAN PAUL L
    Director
    $1.00M
    @ $31.76 · 2025-03-03
    BANCEL STEPHANE J
    Chief Executive Officer
    $5.00M
    @ $31.22 · 2025-03-03
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    V
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    MRNA
    3
    Sells (3M)
    6
    Sells (12M)
    Total value (12M): $11.57M
    KLINGER SHANNON THYME
    Officer
    $173,550
    @ $50.00 · 2026-06-04
    HOGE STEPHEN
    President
    $2.58M
    @ $48.40 · 2026-05-15
    HUSSAIN SHAH ABBAS
    Director
    $264,952
    @ $46.63 · 2026-05-01
    KLINGER SHANNON THYME
    Officer
    $726,047
    @ $52.29 · 2026-03-02
    HOGE STEPHEN
    President
    $7.81M
    @ $48.84 · 2026-02-23
    HUSSAIN SHAH ABBAS
    Director
    $13,910
    @ $27.60 · 2025-12-09
    HUSSAIN SHAH ABBAS
    Director
    $8,736
    @ $28.00 · 2025-06-11
    KLINGER SHANNON THYME
    Officer
    $23,637
    @ $44.68 · 2024-12-09
    KLINGER SHANNON THYME
    Officer
    $4,849
    @ $43.29 · 2024-12-03
    HOGE STEPHEN
    President
    $13,595
    @ $43.30 · 2024-12-03
    KLINGER SHANNON THYME
    Officer
    $60,675
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,452
    @ $42.79 · 2024-11-29
    MOCK JAMES M
    Chief Financial Officer
    $60,761
    @ $42.79 · 2024-11-29
    HOGE STEPHEN
    President
    $12,771
    @ $46.10 · 2024-11-11
    MOCK JAMES M
    Chief Financial Officer
    $42,986
    @ $60.12 · 2024-10-07
    KLINGER SHANNON THYME
    Officer
    $40,539
    @ $73.57 · 2024-09-09
    KLINGER SHANNON THYME
    Officer
    $8,777
    @ $76.99 · 2024-09-03
    HOGE STEPHEN
    President
    $24,483
    @ $76.99 · 2024-09-03
    KLINGER SHANNON THYME
    Officer
    $12,640
    @ $78.02 · 2024-08-29
    HOGE STEPHEN
    President
    $23,408
    @ $78.03 · 2024-08-29
    MOCK JAMES M
    Chief Financial Officer
    $12,640
    @ $78.02 · 2024-08-29
    KLINGER SHANNON THYME
    Officer
    $104,722
    @ $79.39 · 2024-08-28
    MOCK JAMES M
    Chief Financial Officer
    $104,881
    @ $79.40 · 2024-08-28
    HOGE STEPHEN
    President
    $21,363
    @ $84.11 · 2024-08-12
    AFEYAN NOUBAR BOGHOS
    Director
    $1.80M
    @ $119.96 · 2024-07-31
    AFEYAN NOUBAR BOGHOS
    Director
    $1.77M
    @ $117.80 · 2024-07-24
    AFEYAN NOUBAR BOGHOS
    Director
    $1.84M
    @ $122.84 · 2024-07-17
    HOGE STEPHEN
    President
    $1.82M
    @ $121.12 · 2024-07-15
    AFEYAN NOUBAR BOGHOS
    Director
    $1.76M
    @ $117.08 · 2024-07-10
    MOCK JAMES M
    Chief Financial Officer
    $81,465
    @ $118.24 · 2024-07-08
    AFEYAN NOUBAR BOGHOS
    Director
    $1.91M
    @ $127.22 · 2024-06-26
    AFEYAN NOUBAR BOGHOS
    Director
    $2.00M
    @ $133.57 · 2024-06-18
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    V
    2
    Sells (3M)
    17
    Sells (12M)
    Total value (12M): $53.88M
    SUH CHRIS
    Chief Financial Officer
    $3.46M
    @ $324.81 · 2026-05-12
    MCINERNEY RYAN
    Chief Executive Officer
    $10.70M
    @ $340.14 · 2026-04-29
    CARNEY LLOYD A
    Director
    $201,253
    @ $309.62 · 2026-03-11
    MCINERNEY RYAN
    Chief Executive Officer
    $3.66M
    @ $349.18 · 2026-01-02
    ROTTENBERG JULIE B
    General Counsel
    $699,315
    @ $345.00 · 2025-12-11
    MCINERNEY RYAN
    Chief Executive Officer
    $3.57M
    @ $340.07 · 2025-12-11
    TANEJA RAJAT
    Officer
    $7.84M
    @ $330.14 · 2025-12-02
    FABARA PAUL D
    Officer
    $2.50M
    @ $331.45 · 2025-12-02
    TANEJA RAJAT
    Officer
    $2.08M
    @ $330.00 · 2025-11-21
    FABARA PAUL D
    Officer
    $707,917
    @ $325.93 · 2025-11-21
    CARNEY LLOYD A
    Director
    $302,832
    @ $336.48 · 2025-11-04
    MCINERNEY RYAN
    Chief Executive Officer
    $3.58M
    @ $341.00 · 2025-11-03
    MCINERNEY RYAN
    Chief Executive Officer
    $3.59M
    @ $342.30 · 2025-10-01
    MCINERNEY RYAN
    Chief Executive Officer
    $3.65M
    @ $348.57 · 2025-09-02
    ROTTENBERG JULIE B
    General Counsel
    $697,329
    @ $344.02 · 2025-08-18
    MCINERNEY RYAN
    Chief Executive Officer
    $3.60M
    @ $343.13 · 2025-08-14
    MCINERNEY RYAN
    Chief Executive Officer
    $3.05M
    @ $353.82 · 2025-07-01
    FABARA PAUL D
    Officer
    $4.36M
    @ $375.00 · 2025-06-11
    TANEJA RAJAT
    President
    $18.44M
    @ $368.87 · 2025-06-05
    FABARA PAUL D
    Officer
    $17.10M
    @ $370.00 · 2025-06-05
    MCINERNEY RYAN
    Chief Executive Officer
    $3.13M
    @ $362.77 · 2025-06-02
    FABARA PAUL D
    Officer
    $6.32M
    @ $357.45 · 2025-05-12
    FABARA PAUL D
    Officer
    $5.26M
    @ $355.04 · 2025-05-08
    ROTTENBERG JULIE B
    General Counsel
    $889,868
    @ $345.58 · 2025-05-01
    MCINERNEY RYAN
    Chief Executive Officer
    $2.98M
    @ $345.58 · 2025-05-01
    MCINERNEY RYAN
    Chief Executive Officer
    $3.02M
    @ $350.44 · 2025-04-01
    FABARA PAUL D
    Officer
    $13.40M
    @ $340.41 · 2025-03-19
    FABARA PAUL D
    Officer
    $12.88M
    @ $327.20 · 2025-03-14
    MCINERNEY RYAN
    Chief Executive Officer
    $3.13M
    @ $363.00 · 2025-03-03
    ANDRESKI PETER M
    Officer
    $815,314
    @ $349.62 · 2025-02-07
    MAHON TULLIER KELLY
    Officer
    $11.80M
    @ $349.77 · 2025-02-07
    ROTTENBERG JULIE B
    General Counsel
    $874,480
    @ $340.00 · 2025-02-03
    MCINERNEY RYAN
    Chief Executive Officer
    $2.93M
    @ $340.00 · 2025-02-03
    MCINERNEY RYAN
    Chief Executive Officer
    $2.74M
    @ $317.78 · 2025-01-02
    TANEJA RAJAT
    Officer
    $11.15M
    @ $315.55 · 2024-12-13
    MCINERNEY RYAN
    Chief Executive Officer
    $2.73M
    @ $316.90 · 2024-12-02
    FABARA PAUL D
    Officer
    $668,603
    @ $307.97 · 2024-11-22
    ROTTENBERG JULIE B
    General Counsel
    $741,996
    @ $288.49 · 2024-11-01
    MCINERNEY RYAN
    Chief Executive Officer
    $2.49M
    @ $288.49 · 2024-11-01
    MCINERNEY RYAN
    Chief Executive Officer
    $2.39M
    @ $276.97 · 2024-10-01
    MCINERNEY RYAN
    Chief Executive Officer
    $2.38M
    @ $276.37 · 2024-09-03
    ROTTENBERG JULIE B
    General Counsel
    $707,300
    @ $275.00 · 2024-08-29
    MCINERNEY RYAN
    Chief Executive Officer
    $2.37M
    @ $275.00 · 2024-08-29
    MAHON TULLIER KELLY
    Officer
    $10.12M
    @ $267.64 · 2024-08-16
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    MRNA
    FearGreed
    😏Greed(61/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    V
    FearGreed
    😐Neutral(57/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    MRNA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
    V
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (57)
    View MRNA Full AnalysisView V Full Analysis

    Frequently Asked Questions: MRNA vs V

    Is Moderna, Inc. or Visa Inc. more undervalued in 2026?

    Based on our discounted cash flow model, V trades at a -7.6% margin of safety (intrinsic value $304 vs. price $327), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

    Which stock has a wider economic moat, Moderna, Inc. or Visa Inc.?

    V scores 99/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Moderna, Inc. in financial distress?

    MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. V scores 8.1 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, Moderna, Inc. or Visa Inc.?

    Visa Inc. (V) generates a 3.3% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, Moderna, Inc. or Visa Inc.?

    V earns 38.4% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.